 PHILADELPHIA, April 1, 2021 PRNewswire -- Lannett Company, Inc. NYSE: LCI today announced the submission of an Abbreviated New Drug Application ANDA for Fluticasone propionate and Salmeterol inhalation powder 10050 mcg, 25050 mcg and 50050 mcg to the U.S. Food and Drug Administration FDA, by its strategic alliance partner, Respirent Pharmaceuticals Co. Ltd. The product is the generic equivalent of ADVAIR DISKUS of GlaxoSmithKline. 